This video overviews the development of Pharmaco-Kinesis Corp (PKC). as of 2013. With commentary by PKC principals Frank Adell, co-founder and CEO, Josh Shachar, co-founder, CTO and inventor, and Dr. Thomas Chen, Professor of Neurosurgery and Director of Neuro-oncology at USC, the video shows how PKC's innovative breakthroughs in Smart Drug Delivery Systems and Smart Medical Devices is paving the way for new and more effective treatments for cancer patients around the world. Discussed are two of PKC's current technologies that are in development. The first is the Metronomic Biofeedback Pump (MBP). The MBP is an implantable device capable of delivering controlled, targeted doses of chemotherapeutics directly to a cancerous tumor site while at the same time providing physicians real-time data feedback of the treatment's efficacy and wireless remote adjustment of the drug delivery dosage and frequency all while allowing the patient to not be tethered to external equipment. The second is the VEGF Bio-sensor, an implantable micro-chip capable of detecting levels of VEGF-165, a general bio-marker which has been correlated to the presence of cancerous tumor growth in the body, at levels that can inform a physician of potential cancer growth at a much earlier stage then heretofore possible. The VEGF Biosensor not only measures the VEGF-165 biomarker but can report the data in real-time to a monitoring physician through any web-enabled device anywhere in the world. Both products bring promise of new treatment modalities to assist both the medical community and the patient population whose lives can be saved with these advances.